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Editorial
Treating Colon Cancer With a Melanoma
Vaccine? Preposterous?
Vernon K. Sondak, MD and Alfred E. Chang, MD
Dr. Donald Morton and his group have never been
afraid to think outside the box. While the rest of us were
debating whether to do elective node dissections for
melanoma, he developed a technique to identify nodal
micrometastases in the “sentinel” node, revolutionizing
the management of stage I and II melanoma in the
process. But has he gone too far this time? After all,
giving patients with colon cancer a melanoma vaccine!1
That’s crazy—isn’t it?
Maybe not. It certainly bucks the current trend toward
ever more precisely defined single antigen vaccines, such
as the rash of designer peptides that are not merely
disease-specific but actually restricted to use in specific
subsets of patients based on HLA expression. So giving
patients a “gamish” of melanoma cells in hope of engen-
dering an immune response to colon cancer antigens
would seem to be proceeding in the opposite direction:
firing blindly at the immune system and hoping a ‘golden
bullet’ magically hits the target. Nonetheless, the limita-
tions of defined-antigen vaccine strategies are becoming
apparent,2,3 and evidence that polyvalent, autologous,
and allogeneic tumor vaccines can mediate an effective
antitumor immune response is growing.4,5 The question
is no longer “If?” but “How?”
Limitations of Defined Antigen Vaccines
Human tumors develop in a series of evolutionary
steps, during which time they evade the immune sys-
tem’s surveillance mechanisms. Thus, every clinically
detectable tumor is already adept to some degree at
disguising itself from the immune system. Antigenic
heterogeneity is the rule in tumors: even within strongly
antigen-rich tumors there are at least some cells that do
not express the target antigen. Moreover, most tumors
are eventually capable of down-modulating antigen ex-
pression in the face of sustained immune attack. Al-
though it is clear that on occasion immunization with a
single, defined antigen can result in regression of even
extensive tumor, this is the exception and not the rule. So
far, successes of immunotherapy with single antigen
vaccinations have been virtually entirely restricted to
malignant melanoma patients. The possibility exists that
melanoma is a unique tumor arising in a regionally
immunocompromised setting (ultraviolet radiation-ex-
posed skin), not readily generalizable to other solid
tumors.
Even if a tumor lacks antigen expression on a subset of
its cells, a defined antigen vaccine can still induce re-
gression of advanced disease by killing the majority
population of antigen-expressors. Ultimately, unless a
more generalized immune reaction occurs (“epitope
spreading”), the antigen-negative population will grow
out and cause clinical relapse. This limitation is partic-
ularly glaring in the adjuvant therapy setting, where cure
and not transient reduction of tumor burden is the goal. It
may be that this phenomenon explains the results of a
recent phase III clinical trial in which a defined antigen
vaccine (purified GM2 ganglioside conjugated to key-
hole limpet hemocyanin) that achieved high levels of
IgG and IgM antibody induction failed to match standard
therapy with high-dose interferon-alfa 2b in high-risk
melanoma patients.2
Limitations and Benefits of Autologous Vaccines
The use of autologous tumor vaccines, namely, tumor
derived from the patient to be treated, has been evaluated
by several different groups. Autologous tumor vaccines
are attractive because of the high likelihood that any
tumor-associated antigens potentially capable of eliciting
an antitumor immune response will actually be present
within the vaccine. These antigens, however, may be
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present in only limited amounts and must compete for
the immune system’s attention with multiple other irrel-
evant self- and tumor-associated antigens. More prob-
lematic than that, autologous tumor is a limited commod-
ity that involves an invasive procedure to harvest in those
situations where it is obtainable. In melanoma, this may
not be an overwhelming obstacle, because cutaneous,
subcutaneous and nodal deposits of tissue are accessible
in many cases, and the surgery to remove such tumors is
straightforward and rarely debilitating. In renal cell car-
cinoma, justification exists for removing a primary tumor
from a patient with documented metastatic disease,6 but
nephrectomy is a procedure with significant associated
risks of major complications and even death. For colon
cancer, the target of the current investigation,1 the pros-
pects of an autologous vaccine are even poorer. The
primary tumor sits in a bacteria-rich environment that is
ill-suited to generate autologous vaccines, whereas most
metastases are located in the liver or other visceral sites.
Resection of metastatic deposits from colorectal prima-
ries is occasionally undertaken, but extending the surgi-
cal indications for liver resection to include otherwise
non-therapeutic tumor harvests would require far more
evidence of efficacy than exists to date. Acknowledging
the fact that some clinical trials with autologous tumor
vaccines from colonic primaries have been carried out,7
the prospects for widespread application of vaccination
strategies requiring autologous colon cancer cells are
limited to say the least.
Potential of Polyvalent, Allogeneic Vaccines
Allogeneic tumor vaccines provide many of the ben-
efits of autologous tumor, albeit with a lesser degree of
certainty that key regression antigens would be present,
while offering far greater availability. They also offer a
degree of consistency of formulation from patient to
patient that is very attractive to the designers of large-
scale clinical trials.
Which brings us back to our original quandary: does
it make sense to use an allogeneic melanoma vaccine,
chock full of totally irrelevant tumor antigens, to
achieve an immune response against colon cancer—
even if one or more shared antigens are present on the
vaccine? The answer is a qualified yes. Dr. Morton
and co-workers have shown that this approach suc-
cessfully immunized colon cancer patients to the tar-
get shared antigen (TA90), as measured by induction
of humoral and DTH responses. Although there was
some correlation between TA90 immune response and
survival duration, there were no objective antitumor
responses. All of us in the vaccine field have come to
recognize that correlations between immune response
and survival may be epiphenomena rather than cause-
and-effect, and hence cannot be accepted as clear
evidence of vaccine benefit.
Thus we’re left with the bland and somewhat un-
satisfying clinical cliché that “further research is jus-
tified.” Perhaps we can go a step further, though.
Perhaps we can do more than just add additional
patients to single-arm studies that will never fully
define the clinical efficacy of this cross-tumor vacci-
nation approach. Perhaps we can use this novel “out-
side the box” observation to create new clinical trials
that will further dissect the human antitumor immune
system. Consider the potential value of a randomized
phase II trial that compares the allogeneic melanoma
vaccine with a defined antigen vaccine composed of
TA90 antigen alone, using appropriate immunologic
endpoints, in a homogeneous population of patients
with stage IV colorectal cancer. As pointed out by
Habal et al., patients with resected and/or ablated
stage IV disease may be an appropriate population to
consider. Alternatively, the same clinical trial strategy
could be applied to compare the allogeneic melanoma
vaccine with a similarly prepared allogeneic colon
cancer vaccine that expresses similar levels of TA90
antigen. In either case, the goal of such a trial would
be to determine the relative levels of antitumor immu-
nity elicited by the different strategic approaches. Be-
sides examining the humoral responses induced by this
vaccine, T-cell responses may also provide useful
information about other mechanisms which might lead
to tumor rejection. If the allogeneic melanoma vaccine
were superior in eliciting an anti-TA90 immune re-
sponse, it might yet fail to benefit patients because of
the previously expressed reservations about single-
antigen vaccination. Still, just that observation would
constitute yet more proof that thinking outside the box
was anything but preposterous!
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